Multicenter, Randomized, Placebo-Controlled Phase III Study of Pyridoxalated Hemoglobin Polyoxyethylene in Distributive Shock (PHOENIX)* — Jean Louis Vincent (2014) | RDL Network
In this randomized, controlled phase III trial in patients with vasopressor-dependent distributive shock, administration of a pyridoxalated hemoglobin solution decreased the need for vasopressors but was associated with a trend to increased mortality.
Jason J. Luke, Paolo A. Ascierto, Matteo S. Carlino, Jeffrey E. Gershenwald, Jean-Jacques Grob, Axel Hauschild, John M. Kirkwood, Georgina V. Long, Peter Mohr, Caroline Robert, Merrick I. Ross, Richard A Scolyer, Charles H. Yoon, Andrew Poklepovic, Piotr Rutkowski, James R. Anderson, Sama Ahsan, Nageatte Ibrahim, Alexander M.M. Eggermont
Andrew X. Zhu, Olivier Rosmorduc, T.R. Jeffry Evans, Paul J. Ross, Armando Santoro, Flair José Carrilho, Jordi Bruix, Shukui Qin, Paul J. Thuluvath, Josep M. Llovet, Marie-Aude LeBerre, Markus Jensen, Gerold Meinhardt, Yoon‐Koo Kang
Discussion(0)
No comments yet. Be the first to comment.